Nav: Home

Researchers discover first human antibodies that work against all ebolaviruses

May 18, 2017

May 18, 2017 -- (BRONX, NY) -- After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses. The findings, published online today in the journal Cell, could lead to the first broadly effective ebolavirus therapies and vaccines.

Ebolaviruses infections are usually severe, and often fatal. There are no vaccines or treatments approved by the Food and Drug Administration for treating these viruses. Some two dozen ebolavirus outbreaks have occurred since 1976, when the first outbreak was documented in villages along the Ebola River in the Democratic Republic of Congo (formerly Zaire). The largest outbreak in history -- the 2013-16 Western African epidemic -- caused more than 11,000 deaths and infected more than 29,000 people.

Monoclonal antibodies, which bind to and neutralize specific pathogens and toxins, have emerged as one of the most promising treatments for Ebola patients. A critical problem, however, is that most antibody therapies target just one specific ebolavirus. For example, the most advanced therapy -- ZMappTM, a cocktail of three monoclonal antibodies -- is specific for Ebola virus (formerly known as "Ebola Zaire"), but doesn't work against two related ebolaviruses (Sudan virus and Bundibugyo virus) that have also caused major outbreaks.

"Since it's impossible to predict which of these agents will cause the next epidemic, it would be ideal to develop a single therapy that could treat or prevent infection caused by any known ebolavirus," says study co-leader Zachary A. Bornholdt, Ph.D., director of antibody discovery at Mapp Biopharmaceutical, Inc. "Our discovery and characterization of broadly neutralizing human antibodies is an important step toward that goal," adds study co-leader, Kartik Chandran, Ph.D. , professor of microbiology & immunology at Albert Einstein College of Medicine.

The study was also co-led by John M. Dye, Ph.D., chief of viral immunology at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

In earlier research, Dr. Bornholdt and Laura M. Walker, Ph.D., a senior scientist at Adimab, LLC, isolated 349 distinct monoclonal antibodies from a survivor of the 2013-16 Ebola epidemic. In the current study, the multi-institutional research team found that two of those 349 antibodies, known as ADI-15878 and ADI-15742, potently neutralized infection by all five known ebolaviruses in tissue culture. Both antibodies were able to protect animals (mice and ferrets) that had been exposed to a lethal dose of the three major agents: Ebola virus, Bundibugyo virus and Sudan virus.

Follow-up studies showed that the two antibodies isolated from the Ebola patient work by interfering with a critical step in the process by which ebolaviruses infect cells and then multiply inside them. The two antibodies encounter the virus while it's still in the bloodstream, and bind to glycoproteins (proteins to which carbohydrate chains are attached) that project from its surface. The virus, with its hitchhiking antibodies still bound to it, then attaches to a cell and enters the lysosome -- a membrane-bound structure within the cell that is filled with enzymes for digesting foreign and cellular components. The virus must then fuse with the lysosome membrane to escape into the host cell's cytoplasm, where it can multiply. However, the antibodies prevent the virus from breaking out of its lysosomal "prison," thus stopping infection in its tracks.

"Knowing precisely where the antibodies attach to the glycoprotein molecules and when and how they act to neutralize ebolaviruses, we can begin to craft broadly effective immunotherapies," says Dr. Dye. "That knowledge has already allowed us to create a cocktail of monoclonal antibodies that we are testing in larger animal models for possible use in treating infected patients," adds Dr. Bornholdt.

The researchers also pinpointed the human genes that are the likely source of the immune cells that produce the two antibodies. These and other findings could help speed the development of vaccines to prevent ebolavirus infection. "We'd like to synthesize vaccine immunogens [proteins that trigger antibody production] that can elicit the same types of broadly protective antibodies in people," says Dr. Chandran.
-end-
The study is titled "Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses." Other Einstein researchers include co-first author Anna Z. Wec, M.S., Elisabeth K. Nyakatura, Ph.D., Jens Maximilian Fels, Rohit K. Jangra, Ph.D., M.V.Sc., B.V.Sc. & A.H., and Jonathan R. Lai, Ph.D. Additional contributors are co-first author Andrew S. Herbert, Ph.D., Rebekah M. James, and Russell R. Bakken, of USAMRIID, Fort Detrick, MD; Shihua He, Ph.D., Marc-Antoine de La Vega, Wenjun Zhu, Ph.D., and Xiangguo Qiu, M.D., of National Microbiology Laboratory, Public Health Agency of Canada and University of Manitoba, Manitoba, Canada; Charles D. Murin, Ph.D., Hannah L. Turner, and Andrew B. Ward, Ph.D. of The Scripps Research Institute, La Jolla, CA; Eileen Goodwin of Adimab, LLC, Lebanon, NH; and Dafna M. Abelson and Larry Zeitlin, Ph.D. of Mapp Biopharmaceutical Inc., San Diego, CA.

The study was funded by grants from the National Institutes of Health (U19 AI109762), JSTO- Defense Threat Reduction Agency (CB4088 and HDTRA1-13-C-0018), and the Public Health Agency of Canada.

The authors declare no financial conflicts of interest.

About Albert Einstein College of Medicine

Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2016-2017 academic year, Einstein is home to 717 M.D. students, 166 Ph.D. students, 103 students in the combined M.D./Ph.D. program, and 278 postdoctoral research fellows. The College of Medicine has more than 1,900 full-time faculty members located on the main campus and at its clinical affiliates. In 2016, Einstein received more than $160 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit, read our blog, follow us on Twitter, like us on Facebook and view us on YouTube .

About Mapp Biopharmaceutical

Mapp Biopharmaceutical develops monoclonal antibody products for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. The company has advanced two anti-viral antibody-based therapeutics into clinical trials, including a Phase 2 trial of ZMappTM in patients with Ebola Virus Disease. For more information, visit http://www.mappbio.com

About U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID's mission is to provide leading edge medical capabilities to deter and defend against current and emerging biological threat agents. Research conducted at USAMRIID leads to medical solutions-vaccines, drugs, diagnostics, and information-that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit http://www.usamriid.army.mil.

Albert Einstein College of Medicine

Related Antibodies Articles:

Improving research with more effective antibodies
A new study points to the need for better antibody validation, and outlines a process that other labs can use to make sure the antibodies they work with function properly.
How to enable light to switch on and off therapeutic antibodies
IBS researchers have developed a new biological tool that activates antibody fragments via a blue light.
Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.
How new loops in DNA packaging help us make diverse antibodies
It's long been known that our immune cells mix and match bits of genetic code to make new kinds of antibodies to fight newly encountered threats.
Immunological discovery opens new possibilities for using antibodies
Researchers from the University of Turku have discovered a new route that transports subcutaneously administered antibodies into lymph nodes in just a few seconds.
Rheumatoid arthritic pain could be caused by antibodies
Antibodies that exist in the joints before the onset of rheumatoid arthritis can cause pain even in the absence of arthritis, researchers from Karolinska Institutet in Sweden report.
Humanization of antibodies targeting human herpesvirus 6B
A Japanese research group have succeeded in humanization of mouse antibodies that can neutralize the infection caused by human herpesvirus 6B.
Edible antibodies to treat and prevent gastrointestinal disorders
Therapeutic antibodies are increasingly being used in the clinic for the treatment of various diseases.
Antibodies stabilize plaque in arteries
Researchers at Karolinska Institutet in Sweden have found that type IgG antibodies play an unexpected role in atherosclerosis.
Protective antibodies also found in premature babies
Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine.
More Antibodies News and Antibodies Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.